



Post Authorisation Assessments

Lotimil 48 mg Chewable Tablets for Cats (>2.0–8.0 kg) Vm 00879/5049

03 February 2026	Addition of anorexia, lethargy, tachypnoea, ataxia, muscle tremor, hyperactivity and pruritus as AE to align with reference product.
09 October 2025	Minor change to an approved test procedure for an active substance.
19 August 2025	Addition of a primary packaging site of a non-sterile finished product. Addition of a secondary packaging site of a finished product.
04 June 2025	Minor changes to an approved test procedure for the finished product.
24 April 2025	Change in the specification parameters of an intermediate. Change in the specification parameters of an intermediate. Change in the specification parameters of an intermediate. Minor change in the manufacturing process of an intermediate.
24 April 2025	Change in the manufacturer of an intermediate.
23 April 2025	Change in the name of a supplier of a starting material used in the manufacture of the active substance. Deletion of a supplier of a starting material for an active substance.